ObsEva’s uterine fibroids drug linzagolix has hit a snag at the FDA, portending a likely delayed regulatory decision. Rather than stick it out and see if its small molecule can match up against commercialized products from AbbVie and Myovant, ObsEva plans to give up rights to the drug as part of a corporate restructuring.
Myovant hormonal drug Myfembree has won FDA approval as a treatment for uterine fibroid bleeding. The regulatory decision clears the way for the pill to compete against a similar AbbVie drug, but with a dosing advantage.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The Israeli company's technology uses the power of focused ultrasound guided by MR imaging to target conditions like essential tremor, Parkinson's disease and neuropathic pain.
The ExAblate device's label, an ultrasound technology designed to treat uterine fibroids, has been adapted in order for it to be available to women who want to keep their uterus intact while still having the option to get pregnant.